{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:47:35Z","timestamp":1760622455144,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":3030,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.rmed.2004.11.002","type":"journal-article","created":{"date-parts":[[2005,1,29]],"date-time":"2005-01-29T03:49:10Z","timestamp":1106970550000},"page":"S1-S10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"S1","title":["Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma"],"prefix":"10.1016","volume":"99","author":[{"given":"Narinder","family":"Chopra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Rimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mair","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2004.11.002_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta5260","article-title":"Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease","volume":"5","author":"Brocklebank","year":"2001","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.rmed.2004.11.002_bib2","unstructured":"Command paper no.977; Treaty series 1990 (19); Montreal protocol. Substances that deplete the ozone layer. Montreal, 16th September 1987. 2004."},{"key":"10.1016\/j.rmed.2004.11.002_bib3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1183\/09031936.97.10040815","article-title":"An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)","volume":"10","author":"Boyd","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2004.11.002_bib4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/BF01958642","article-title":"Efficacy and safety of salmeterol in childhood asthma","volume":"154","author":"Lenney","year":"1995","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.rmed.2004.11.002_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/thx.48.2.148","article-title":"Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group","volume":"48","author":"Lundback","year":"1993","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2004.11.002_bib6","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.2042-7158.1996.tb05980.x","article-title":"Twenty-eight-day double-blind safety study of an HFA-134a inhalation aerosol system in healthy subjects","volume":"48","author":"Harrison","year":"1996","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.rmed.2004.11.002_bib7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/00045391-199611000-00005","article-title":"Pharmacokinetics of HFA-134a","volume":"3","author":"Harrison","year":"1996","journal-title":"Am J Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.rmed.2004.11.002_bib8","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1089\/jam.1995.8.Suppl_1.S-35","article-title":"Clinical pharmacology of HFA134a","volume":"8","author":"Ventresca","year":"1995","journal-title":"J Aerosol Med"},{"issue":"Suppl.","key":"10.1016\/j.rmed.2004.11.002_bib9","first-page":"509P","article-title":"GR106642X, a non-chlorinated propellant for use in metered dose inhalers","volume":"37","author":"Denyer","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rmed.2004.11.002_bib10","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/bmj.310.6995.1639a","article-title":"GR106642X","volume":"310","author":"Taggart","year":"1995","journal-title":"Br Med J"},{"key":"10.1016\/j.rmed.2004.11.002_bib11","first-page":"161","article-title":"Efficacy of a new non-ozone depleting formulation for salbutamol","volume":"5","author":"Custovic","year":"1995","journal-title":"J Pharm Med"},{"key":"10.1016\/j.rmed.2004.11.002_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1081-1206(10)62385-X","article-title":"Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction","volume":"88","author":"Hawksworth","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmed.2004.11.002_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1081-1206(10)63302-9","article-title":"Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma","volume":"86","author":"Lumry","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"Suppl. B","key":"10.1016\/j.rmed.2004.11.002_bib14","first-page":"S29","article-title":"Clinical efficacy and safety of fluticasone propionate 250 \u03bcg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group","volume":"94","author":"Tonnel","year":"2000","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2004.11.002_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/rmed.1999.0678","article-title":"Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe inhaler for the treatment of paediatric asthma","volume":"94","author":"Farmer","year":"2000","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2004.11.002_bib16","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.rmed.2004.11.013","article-title":"Development and performance of a new hydrofluroalkane (HFA 134A) based metered dose inhaler (MDI) of salmeterol","volume":"99","author":"Peyron","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2004.11.002_bib17","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.rmed.2004.11.005","article-title":"Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects","volume":"99","author":"Kempsford","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2004.11.002_bib18","unstructured":"GlaxoSmithKline. SLGT39\u2014A multi-centre, randomised, double-blind, parallel group study to compare the efficacy and tolerability of salmeterol (50 mcg bid) administered by pressurised inhaler propelled by a mixture of propellants 11 and 12 or by an alternative propellant, GR106642X in adult patients with reversible airways obstruction, Data on file. 1996."},{"key":"10.1016\/j.rmed.2004.11.002_bib19","unstructured":"GlaxoSmithKline. SLPT18\u2014A multicentre, multi-national, randmoised, double-blind, parallel group study to compare the efficacy and tolerability of salmeterol (50 mcg bd) administered by pressurised inhaler propelled by a mixture of propellants 11 and 12 or by an alternative propellant, GR106642X for a period of twelve months in children with reversible airways obstruction, Data on file. 1996."},{"issue":"Suppl. 33","key":"10.1016\/j.rmed.2004.11.002_bib20","first-page":"101s","article-title":"Effect of fine particles mass (FPM) on the bronchodilator and bronchoprotective properties of salmeterol","volume":"18","author":"Langley","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2004.11.002_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1399-3003.1999.14a06.x","article-title":"What are minimal important changes for asthma measures in a clinical trial?","volume":"14","author":"Santanello","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2004.11.002_bib22","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. National Institutes for Health: Bethesda; 2002."},{"key":"10.1016\/j.rmed.2004.11.002_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/bmj.313.7048.36","article-title":"Trials to assess equivalence","volume":"313","author":"Jones","year":"1996","journal-title":"Br Med J"},{"key":"10.1016\/j.rmed.2004.11.002_bib24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1378\/chest.120.4.1253","article-title":"Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD","volume":"120","author":"Taylor","year":"2001","journal-title":"Chest"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611104004287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611104004287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:14:21Z","timestamp":1760609661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611104004287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":24,"alternative-id":["S0954611104004287"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2004.11.002","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2005,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2004.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}